James Bates on Shifting Perspectives: From AI as a Job Threat to AI as a Vital Workforce Aid in Healthcare

A significant advancement in awareness and patient care.
Step into the transformative world of healthcare with James Bates, an accomplished CEO, entrepreneur, and board member who has driven high-growth plans for leading technology companies. As the Chairman and Founder of AdviNow Medical, James has conceptualized a groundbreaking vision, raised capital, and launched the world's first Artificial Intelligence and Augmented Reality-driven automated medical visit system. Join us for an illuminating conversation with James Bates, a visionary leader in healthcare technology.

Advancements in the biological aspects of healthcare, particularly in the field of vaccines and treatments through gene therapy. This opens up new possibilities in healthcare. 

Media 7: Would you like to share a bit about your personal journey and what led you to focus on revolutionizing healthcare through AI and AR with AdviNOW Medical?
James Bates:
I've been in the high technology field for 25 years since graduating from school. I had the opportunity to join Bell Laboratories, be part of the world's first digital cell phone chipset, which sold billions of units over the years in satellite communication systems. Then, I had the opportunity to join a startup named Silicon Laboratories. We manufactured transceivers for cell phones and microcontrollers for Internet of Things devices. I also had the opportunity to oversee the international operations for them, and the business grew to over half a billion dollars, becoming a very successful company.

Subsequently, I relocated to the Bay Area and had the opportunity to work at Maxim. We partnered with companies such as Apple, Nest, and Google, requiring small-sized, low-power, high-precision components for Internet of Things applications. Later, I moved to Arizona and worked for a company called Free scale, where we developed the most comprehensive solution for self-driving vehicle technologies and advanced driver assistance systems. We were a global leader in this field. In 2016, we sold that business, and as an officer of the company, it seemed like the right time for me to retire.

Upon retirement, I faced a two-year non-compete agreement, which led me to explore new opportunities unrelated to my previous career. Healthcare piqued my interest because it is one of the most pressing issues of our time. Millions of people lack access to healthcare, leading to deteriorating health and poor quality of life. As a society, we need to find a compassionate and equitable way to support these individuals.

My initial venture into the healthcare industry involved considering the purchase of medical practices. However, I discovered that most of them in the United States were financially unviable, with many operating at a loss. As an investor, it didn't make sense to acquire unprofitable medical practices.

Consequently, I encountered a gentleman who operated a chain of urgent care centers that he wanted to sell. As I delved into these practices, I conducted a Six Sigma cost analysis, scrutinizing every aspect of the operation. I observed that doctors spent about two-thirds of their time on clerical tasks, despite being the most highly skilled and respected individuals in the clinic. This work didn't require a medical license but necessitated medical knowledge.

Upon closer examination, I identified two dimensions of this knowledge: coding systems related to healthcare regulations and all the administrative aspects that doctors learned to ensure they got paid and avoided legal issues. The second dimension involved the medical aspect, such as understanding diseases, symptoms, and treatments.

My solution was to apply technology similar to what we used in the self-driving vehicle industry to replicate a physician's decision-making processes using artificial intelligence. We also replicated an administrator's decision-making process to automate all the clerical work. This led to the founding of AdviNow Medical, a company that uses artificial intelligence to eliminate the two-thirds of a doctor's time spent on clerical work. As a result, clients who use our platform enable doctors to see two to three times more patients per day compared to those who don't. This not only makes these clinics profitable but also contributes to reducing the overall cost of healthcare.

M7: How is your organization utilizing AI to improve patient outcomes or streamline healthcare operations?
JB:
Yeah, for the system to eliminate the clerical burden, enabling physicians to see more patients and reduce patient healthcare costs, the AI needs to replicate a physician's decision-making processes. Many companies in the field refer to themselves as AI users of what's known as decision trees, which is how doctors are trained in medical school. However, the reality is that the complexity of these decision trees makes it nearly impossible to structure effectively. Hence, Happy Created has devised a mathematical model that mimics a physician's cognitive processes. We utilize a natural language processing engine to extract information from publicly available, peer-reviewed literature.

Using this data, we automatically establish correlations between symptoms, illnesses, treatments, and outcomes. With these relationships, the AI can replicate a physician's decision-making, enabling it to diagnose over 10,000 illnesses and provide the most appropriate treatment plan. This represents true AI, which, frankly, is quite rare in the industry today.

M7: Can you share details about your organization's 'Digital Front Door' strategy and how it has enhanced patient engagement and access to care?
JB:
The digital front door serves as a patient touch point. When the pandemic emerged, most patients had to resort to using some form of digital front door to schedule their doctor visits and interact with their physicians. Many patients found this experience extremely frustrating.

They encountered issues such as having to input a substantial amount of information and then the doctor not even reviewing what they had provided. This unfortunate reality is characteristic of most digital front doors in existence.

Happy Medical Solutions comprises five distinct components, with the digital front door being just one of them. However, because it is the initial point of contact with the patient, it is of paramount importance that it is user-friendly and intuitive. Additionally, a safety protocol is in place for patients who either do not wish to use it or encounter difficulties.

In such cases, they can seek human assistance to guide them through the process. AdviNow is one of the few companies worldwide that offers this comprehensive support system for their digital front door, allowing a human to assist those who are hesitant or struggling with the technology, while harnessing revolutionary artificial intelligence.

Read more: ‘AI will assist in creating a personalized experience for each individual,’ says Alexey Gubarev


The healthcare industry, post-COVID, faces substantial challenges that are causing financial losses.

M7: In your view, what are the most significant trends currently shaping the healthcare industry?
JB:
There are two key aspects to consider. Firstly, there's the digitization of healthcare, and AdviNow plays a significant role in this process. Physicians have been increasingly burdened with healthcare responsibilities, and the regulatory environment has grown considerably more complex. Navigating this landscape has become almost impossible. Therefore, automating the entire patient journey is one of the most crucial developments in healthcare, and AdviNow is at the forefront of this transformation.

The second noteworthy trend pertains to advancements in the biological aspects of healthcare, particularly in the field of vaccines and treatments through gene therapy. This opens up new possibilities in healthcare, where we can potentially develop vaccines to prevent conditions like cancer from occurring in the first place, rather than solely focusing on treating these conditions once they manifest. The ability to proactively maintain human health, as opposed to reacting to illness, represents another major trend in the industry.

M7: In your opinion, what are the most significant challenges and opportunities on the horizon for the healthcare industry?
JB:
The healthcare industry, post-COVID, faces substantial challenges that are causing financial losses. During the pandemic, government subsidies related to COVID made nearly every healthcare institution profitable. However, with the cessation of these subsidies, the vast majority of healthcare entities are now experiencing financial difficulties.

This loss of profitability has led to a slowdown in the progress they were making in terms of technological advancements and advanced medical practices. The need to make budget cuts has presented a significant challenge. In this scenario, what we require are forward-thinking individuals within these healthcare organizations who can drive the adoption of technology as a solution to address these budgeting issues. Instead of slowing down and adhering to traditional practices, we need to embrace technology to overcome these challenges.

M7: Would you like to discuss the types of decision support tools or systems employed within your organization to aid clinical decision-making and improve patient care?
JB:
AdviNow collects patient information and then presents a one-page summary to the doctor. This summary streamlines the review and verification process, and the doctor can consult with the patient to provide guidance. Additionally, the AI assists in coding all essential information, ensuring that the doctor gets paid for the visit.

This comprehensive summary covers everything the doctor needs to know about the patient for diagnosis and treatment. It not only details the history of the current illness and its correlations with diseases but also identifies any care gaps related to comorbidities. This one-page summary equips the physician with all the necessary information for a quick and efficient evaluation, setting AdviNow apart from other decision support systems available.

M7: The components of AdviNOW Medical's technology offer unique solutions for improving healthcare delivery. How does content syndication help in spreading the message and engaging with a broader audience regarding these innovative components?
JB:
Our primary objective is to ensure that every healthcare provider and healthcare institution is aware of the availability of these tools. Therefore, our goal is to disseminate this information to reach as many people as possible. In doing so, they can harness these tools to safeguard the financial health of their hospital systems or clinic chains, address issues related to provider burnout, and, most importantly, ensure that they serve their patients effectively. This awareness is crucial for them to comprehend and shape the future of medicine.

M7: Would you like to share how does AdviNOW Medical leverage advertising strategies to effectively communicate its mission and the transformative power of its healthcare solutions?
JB:
AdviNow doesn't actively market outside of the industry. However, we participate in trade shows and engage with industry leaders. Currently, our primary focus is on these activities. Although our intention is to expand our marketing efforts, our current approach relies on word-of-mouth recommendations from key clients, partners, and individuals with success stories that are featured in the medical press.

M7: In your journey with AdviNOW Medical, what role has content creation played in educating healthcare professionals and the public about the benefits of AI and AR in healthcare?
JB:
The messaging surrounding artificial intelligence has evolved over the years. Pre-pandemic, people were highly concerned about AI replacing their jobs. However, in the post-pandemic era, these worries have diminished. Instead, people are now seeking AI to assist them due to the overwhelming nature of their jobs. This signifies a significant shift in the messaging from 'AI is a job threat' to 'AI is a job aid.'

M7: In what ways does AdviNOW Medical actively engage with healthcare professionals, policymakers, and the broader community to share its vision and insights as a thought leader in the industry?
JB:
I sit on multiple boards, one of which is the AZ Bio Organization of Arizona. Through this role, we engage with government officials, hospital system leaders, and regulators. We aim to help them grasp the potential of artificial intelligence in addressing their challenges. We do this through participation in significant governmental organizations and national government entities in the United States, where I serve on boards and in leadership positions. Additionally, trade shows provide another platform for us to effectively communicate this message.

Read more: 'AI is only as smart as the data and the people behind it', says Kyle Ryan


Forefront of an artificial intelligence revolution that allows the healthcare industry to return to its roots.


M7: How do you envision the healthcare landscape evolving in the next 5-10 years?
JB:
Over the next five years, healthcare companies are likely to leverage solutions like ADP Now to eliminate overhead. This will result in increased patient engagement and, ultimately, enable physicians to dedicate more time to their patients and less to clerical tasks. Looking ahead over the next 10 to 15 years, artificial intelligence is expected to play an expanding role in diagnosing straightforward illnesses. This gradual progression will empower physicians to focus on the human aspect of care and address complex conditions, marking a significant advancement in awareness and patient care.

M7: As we conclude, is there a key takeaway or message you'd like to leave our audience with, particularly for those interested in the intersection of AI, AR, and healthcare innovation?
JB:
The key takeaway here is that we are at the forefront of an artificial intelligence revolution that allows the healthcare industry to return to its roots. In this scenario, physicians can dedicate the majority of their time to patient care, rather than dealing with government regulations and payment codes. Physicians have a strong desire for this shift, and artificial intelligence makes it possible within our existing government regulatory framework.

ABOUT ADVINOW MEDICAL

AdviNow Medical stands out as a recognized leader in healthcare technology. Today's healthcare landscape is characterized by soaring costs, inefficiencies, and prolonged wait times, all of which pose significant barriers to accessing care. Its innovative technology harnesses the power of Artificial Intelligence and Augmented Reality to reshape this reality. AdviNOW's commitment to revolutionizing healthcare delivery has not gone unnoticed. IT proudly received the Outstanding Achievement in Healthcare Delivery award from the 2018 AZBig Media Healthcare Leadership Awards and the AZBio Fast Lane Award for the groundbreaking healthcare delivery technology. To Know more please visit; https://advinow.com/.

More C-Suite on deck

Q&A with Anna Baecklund, CTO & Founder at Oppioo

Media 7 | September 21, 2021

Anna Baecklund, CTO & Founder at Oppioo, is a Data Scientist Leader, A skilled communicator capable of explaining complex issues with clarity to diverse audiences. With MSc in engineering physics, Anna is responsible for leading innovation using data science including the development of new insights, advanced modelling techniques, and AI capabilities. With Oppio, An AI companion app, she aims to motivate cancer patients who want to speed up and improve their rehab.

Read More

Q&A with Matthew Sappern, CEO at PeriGen

Media 7 | September 30, 2021

Matthew Sappern, CEO at PeriGen, had served as a corporate officer for Eclipsys Corporation before and during its merger with Allscripts. Leading up to the merger, Sappern served as Eclipsys Senior Vice President of Professional Services, responsible for the company’s $100M consulting, implementation and training P&L. Sappern joined Eclipsys in January 2003, as VP of product development in the software engineering division. Over a time of three years, he came to run 75 percent of the development operation and oversaw the delivery of three critical enterprise software releases in record time for the company.

Read More

'AI is only as smart as the data and the people behind it', says Kyle Ryan

Media 7 | May 17, 2023

Kyle Ryan believes that innovative concepts, data-driven insights, precise engineering, and efficient execution combine to create great products. He also believes that leadership is essential for innovation. Read on to know his thoughts on the role of leadership and technology in healthcare industry.

Read More

Q&A with Anna Baecklund, CTO & Founder at Oppioo

Media 7 | September 21, 2021

Anna Baecklund, CTO & Founder at Oppioo, is a Data Scientist Leader, A skilled communicator capable of explaining complex issues with clarity to diverse audiences. With MSc in engineering physics, Anna is responsible for leading innovation using data science including the development of new insights, advanced modelling techniques, and AI capabilities. With Oppio, An AI companion app, she aims to motivate cancer patients who want to speed up and improve their rehab.

Read More

Q&A with Matthew Sappern, CEO at PeriGen

Media 7 | September 30, 2021

Matthew Sappern, CEO at PeriGen, had served as a corporate officer for Eclipsys Corporation before and during its merger with Allscripts. Leading up to the merger, Sappern served as Eclipsys Senior Vice President of Professional Services, responsible for the company’s $100M consulting, implementation and training P&L. Sappern joined Eclipsys in January 2003, as VP of product development in the software engineering division. Over a time of three years, he came to run 75 percent of the development operation and oversaw the delivery of three critical enterprise software releases in record time for the company.

Read More

'AI is only as smart as the data and the people behind it', says Kyle Ryan

Media 7 | May 17, 2023

Kyle Ryan believes that innovative concepts, data-driven insights, precise engineering, and efficient execution combine to create great products. He also believes that leadership is essential for innovation. Read on to know his thoughts on the role of leadership and technology in healthcare industry.

Read More

Related News

Health Technology

Axxess Launches New Axxess Connect Solution to Accelerate Health Information Exchange

Axxess | January 23, 2024

Axxess, the leading global technology innovator for healthcare at home, launched a new product called Axxess Connect, a groundbreaking interoperability solution. This new product will revolutionize the way Axxess users connect and share data with healthcare providers and specialists, further enhancing care coordination, improving patient outcomes and driving the future by enabling new care models and value-based care. "Axxess Connect is a new benchmark for interoperability in healthcare," says Tim Ingram, Executive Vice President of Interoperability at Axxess. "By working with our partner Kno2 we can now connect our solutions to help accelerate the exchange of health information securely across any network. This means our clients will have easier access to a broader range of providers and specialists, making data sharing and referrals more efficient." By being Kno2 Connected™, Axxess Connect, enables the secure, effortless, and maximized exchange of patient information across patients, providers, payers and HIT vendors. ­­­­The solution meets data security and compliance requirements in accordance with HITRUST and HIPAA regulation for privacy, data sharing and healthcare communication standards supported by national and regional frameworks including Direct Trust, Carequality and most recently, TEFCA. This ensures that patient data is interoperable, secured and protected when shared across systems. "Our collaboration with Kno2 not only improves the overall experience for our users, but it also reduces the administrative load on healthcare providers," said Ingram. "By minimizing time spent on administrative tasks, our clients can focus more on providing quality patient care." Added Theresa Bell, Co-founder, President and Chief Technology Officer of Kno2: "By seamlessly connecting Axxess users with healthcare providers and specialists, we are breaking down barriers and revolutionizing the way data is shared in every care setting. Axxess Connect represents the power of the partnership and the value of being Kno2 Connected. Together, we are revolutionizing care delivery and thoughtfully solving healthcare's biggest problems." Axxess Connect will first be available to Axxess Palliative Care clients before eventually being rolled out to the entire Axxess suite of solutions for home health, hospice and home care. About Axxess Axxess is the leading global technology innovator for healthcare at home, focused on solving the most complex industry challenges. Trusted by more than 9,000 organizations that serve more than 5 million patients worldwide, Axxess offers a complete suite of easy-to-use software solutions that empower home health, home care, hospice, and palliative providers to make healthcare in the home human again. Multiple independent certifications have confirmed that Axxess has the most secure and industry-compliant software available for providers. The company's collaborative culture focused on innovation and excellence is recognized nationally as a "Best Place to Work."

Read More

Healthcare Analytics

SHL Medical partners with SteriPack Group to set up final assembly service

SHL Medical | January 24, 2024

SHL Medical, a world-leading solutions provider of advanced drug delivery systems and SteriPack Group, renowned global supplier of secondary packing and final assembly services to the pharmaceutical industry, enter a non-exclusive strategic partnership. Together, they aim to establish a pre-validated final assembly service at the SteriPack facility in Poland, enhancing the overall flexibility of supply chain strategies for their customers. In addition to SHL Medical's existing final assembly, labeling, and packaging­ services in the United States, this collaboration extends high-quality CMO options to Europe. Markus Puusepp, SHL Medical's Chief Growth Officer, expressed enthusiasm about the partnership, stating "This partnership is a significant addition to the Molly® platform value proposition. We share common values with SteriPack, from focus on the customer to a commitment to quality, making the decision to collaborate straightforward." Recognizing the importance of flexibility and time-to-market, especially in clinical production, the partnership with SteriPack will offer SHL Medical's customers highly flexible and personalized final assembly and packaging solutions. This is particularly beneficial for small batch handling in clinical supply and niche markets like rare diseases. Emphasizing the comprehensive capabilities of the Molly platform, SHL Medical aims to deliver right-sized solutions that ensure improved service, faster timelines, and a more streamlined supply chain for its diverse customer base. John Ward, SteriPack Group's VP Pharmaceutical Solutions commented "SteriPack Group looks forward to supporting SHL Medical and their customers in providing quality and flexible solutions to a fast- moving market. With an emphasis on creating service solutions designed around specific customer requirements, this partnership will make the process of working with the Molly® platform an easy decision." About SHL Medical As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by its company purpose – Enabling Patients' Independence – SHL Medical offers patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. It also offers final assembly, labeling, and packaging solutions for its drug delivery systems. In response to the rising trend in home therapy, SHL Medical has increased its developmental work in the digital healthcare sector to help improve the drug delivery ecosystem. Located across Switzerland, Taiwan, Sweden, and the US, SHL Medical's global team of experts collaborate seamlessly as one team in utilizing its comprehensive in-house manufacturing capabilities. Its solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into its designs and processes to contribute to a cleaner earth. About SteriPack Group SteriPack Group is a globally renowned contract packing and manufacturing organisation serving the pharmaceutical and medical device sectors respectively. With a strong emphasis on innovation, quality and compliance, SteriPack's services to the pharmaceutical industry include device design and development, final assembly, labelling, secondary packing, serialisation and aggregation of injectable formats including vials, pre-filled syringes, and autoinjectors. SteriPack's tailored customer-focused solutions make it an ideally suited supplier for small to medium-sized batch volumes required for a growing market of targeted therapies as well as clinical trials. Its proven capabilities in cleanroom assembly and labelling as well as secondary packing services for drug delivery systems and medical devices, combined with significant investment into growing cold chain storage capacity, have helped to make it a trusted partner to top global pharmaceutical companies.

Read More

Medical Devices

Canon Medical Systems and Olympus Announce Business Alliance regarding Endoscopic Ultrasound Systems

Canon Medical Systems | January 15, 2024

Canon Medical Systems Corporation and Olympus Corporation announced that we have reached an agreement to collaborate on Endoscopic Ultrasound Systems. Canon Medical will develop and manufacture diagnostic ultrasound systems used in Endoscopic Ultrasonography1 (EUS), and Olympus will perform the sales and marketing efforts. The aim of this collaboration between Canon's Aplio i8002 diagnostic ultrasound system for EUS and Olympus' Ultrasound Endoscope3 is to provide the market with advanced EUS equipment capable of delivering high-quality image diagnoses. Canon Medical and Olympus are focusing on technological advancements and enhancing diagnostic performance in the EUS field, with plans for global expansion, starting in Japan and Europe. Canon Medical has a history of more than 100 years in the diagnostic imaging systems business, including X-ray diagnostic systems, CT, MRI, and ultrasound diagnostic systems, and provides products and services to more than 150 countries and regions worldwide. Canon Medical has been a leading company in the development of diagnostic ultrasound systems since the 1960s and has pioneered the development of A-mode (Amplitude display mode) systems for neurosurgery and linear electronic scanning systems, among others. Canon Medical's strengths lie in its advanced ultrasound image quality and proprietary technologies, such as D-THI, an image quality enhancement technology, and SMI, an imaging technology that enables the delineation of extremely slow and fine blood flow, which has been difficult to image in the past. Olympus has contributed to elevating the standard of care through early detection, diagnosis and staging, and minimally invasive treatment since developing the world’s first practical gastrocamera. In the field of EUS, Olympus has worked closely with physicians to develop new equipment to enhance imaging and diagnostic methods and expand procedures, helping gain and maintain a high share of the global market. Through our collaboration, the two companies will achieve further qualitative improvements in the quality of images and performance in diagnosis and minimally invasive treatment of EUS, ultimately contributing to facilitate the early detection of diseases. Comment from Toshio Takiguchi, President and CEO, Canon Medical Systems Corporation “We have been promoting our business with diagnostic imaging at its core under the philosophy of 'Made for Life,' which expresses our desire to contribute to medical care that protects precious lives. We have a long history in diagnostic ultrasound systems and have developed unique technologies that contribute to the early detection of diseases in cooperation with doctors around the world. We are very pleased to collaborate with Olympus, a leading endoscope manufacturer, in the EUS field, which we have not been able to cover adequately until now, to deliver superior solutions to more patients.” Comment from Frank Drewalowski, Executive Officer and Endoscopic Solutions Division Head, Olympus Corporation “Olympus aims to improve patients’ quality of life through early diagnosis made available with Endoscopic Ultrasound Systems. In the field of EUS, diagnostic ultrasound systems are very important, and we are pleased to have a cooperative relationship with Canon Medical, which has advanced ultrasound imaging technology. Canon Medical and Olympus will continue to introduce products and technology that address the needs of the patients, healthcare professionals, and the broader medical industry.” This examination uses ultrasound attached to the tip of an endoscope to observe the outer organs (pancreas, gallbladder, bile ducts, liver, etc.) from the stomach and duodenum. Compared to the approach from the body surface, the target organs can be observed at close range, allowing detailed diagnosis with clearer images. In the diagnosis of pancreatic cancer, EUS is recognized as having the same diagnostic capability as contrast-enhanced CT and MRI in the "Guidelines for Pancreatic Cancer Treatment (2022)" in Japan. EUS-FNA (Endoscopic Ultrasonography-FNA: a test to collect tumor cells using an ultrasound endoscope) enables qualitative tissue diagnosis by minimally invasive cell and tissue collection and is established worldwide as a diagnostic method when pancreatic cancer is suspected. In addition to endoscopic retrograde cholangiopancreatography (ERCP), which is the first choice for stent placement for obstructive jaundice, endoscopic ultrasound-assisted biliary drainage (EUS-BD) using the EUS-FNA technique is now available. With the advent of these devices, the endoscopic treatment area of Interventional EUS has been attracting increasing attention in recent years. About Canon Medical Systems Canon Medical offers a full range of diagnostic medical imaging solutions including CT, Diagnostic and Interventional X-ray, Ultrasound and MR, as well as a full suite of Healthcare IT solutions, across the globe. In line with our continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features. At Canon Medical, we work hand in hand with our partners - our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life About Olympus At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world.

Read More

Health Technology

Axxess Launches New Axxess Connect Solution to Accelerate Health Information Exchange

Axxess | January 23, 2024

Axxess, the leading global technology innovator for healthcare at home, launched a new product called Axxess Connect, a groundbreaking interoperability solution. This new product will revolutionize the way Axxess users connect and share data with healthcare providers and specialists, further enhancing care coordination, improving patient outcomes and driving the future by enabling new care models and value-based care. "Axxess Connect is a new benchmark for interoperability in healthcare," says Tim Ingram, Executive Vice President of Interoperability at Axxess. "By working with our partner Kno2 we can now connect our solutions to help accelerate the exchange of health information securely across any network. This means our clients will have easier access to a broader range of providers and specialists, making data sharing and referrals more efficient." By being Kno2 Connected™, Axxess Connect, enables the secure, effortless, and maximized exchange of patient information across patients, providers, payers and HIT vendors. ­­­­The solution meets data security and compliance requirements in accordance with HITRUST and HIPAA regulation for privacy, data sharing and healthcare communication standards supported by national and regional frameworks including Direct Trust, Carequality and most recently, TEFCA. This ensures that patient data is interoperable, secured and protected when shared across systems. "Our collaboration with Kno2 not only improves the overall experience for our users, but it also reduces the administrative load on healthcare providers," said Ingram. "By minimizing time spent on administrative tasks, our clients can focus more on providing quality patient care." Added Theresa Bell, Co-founder, President and Chief Technology Officer of Kno2: "By seamlessly connecting Axxess users with healthcare providers and specialists, we are breaking down barriers and revolutionizing the way data is shared in every care setting. Axxess Connect represents the power of the partnership and the value of being Kno2 Connected. Together, we are revolutionizing care delivery and thoughtfully solving healthcare's biggest problems." Axxess Connect will first be available to Axxess Palliative Care clients before eventually being rolled out to the entire Axxess suite of solutions for home health, hospice and home care. About Axxess Axxess is the leading global technology innovator for healthcare at home, focused on solving the most complex industry challenges. Trusted by more than 9,000 organizations that serve more than 5 million patients worldwide, Axxess offers a complete suite of easy-to-use software solutions that empower home health, home care, hospice, and palliative providers to make healthcare in the home human again. Multiple independent certifications have confirmed that Axxess has the most secure and industry-compliant software available for providers. The company's collaborative culture focused on innovation and excellence is recognized nationally as a "Best Place to Work."

Read More

Healthcare Analytics

SHL Medical partners with SteriPack Group to set up final assembly service

SHL Medical | January 24, 2024

SHL Medical, a world-leading solutions provider of advanced drug delivery systems and SteriPack Group, renowned global supplier of secondary packing and final assembly services to the pharmaceutical industry, enter a non-exclusive strategic partnership. Together, they aim to establish a pre-validated final assembly service at the SteriPack facility in Poland, enhancing the overall flexibility of supply chain strategies for their customers. In addition to SHL Medical's existing final assembly, labeling, and packaging­ services in the United States, this collaboration extends high-quality CMO options to Europe. Markus Puusepp, SHL Medical's Chief Growth Officer, expressed enthusiasm about the partnership, stating "This partnership is a significant addition to the Molly® platform value proposition. We share common values with SteriPack, from focus on the customer to a commitment to quality, making the decision to collaborate straightforward." Recognizing the importance of flexibility and time-to-market, especially in clinical production, the partnership with SteriPack will offer SHL Medical's customers highly flexible and personalized final assembly and packaging solutions. This is particularly beneficial for small batch handling in clinical supply and niche markets like rare diseases. Emphasizing the comprehensive capabilities of the Molly platform, SHL Medical aims to deliver right-sized solutions that ensure improved service, faster timelines, and a more streamlined supply chain for its diverse customer base. John Ward, SteriPack Group's VP Pharmaceutical Solutions commented "SteriPack Group looks forward to supporting SHL Medical and their customers in providing quality and flexible solutions to a fast- moving market. With an emphasis on creating service solutions designed around specific customer requirements, this partnership will make the process of working with the Molly® platform an easy decision." About SHL Medical As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by its company purpose – Enabling Patients' Independence – SHL Medical offers patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. It also offers final assembly, labeling, and packaging solutions for its drug delivery systems. In response to the rising trend in home therapy, SHL Medical has increased its developmental work in the digital healthcare sector to help improve the drug delivery ecosystem. Located across Switzerland, Taiwan, Sweden, and the US, SHL Medical's global team of experts collaborate seamlessly as one team in utilizing its comprehensive in-house manufacturing capabilities. Its solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into its designs and processes to contribute to a cleaner earth. About SteriPack Group SteriPack Group is a globally renowned contract packing and manufacturing organisation serving the pharmaceutical and medical device sectors respectively. With a strong emphasis on innovation, quality and compliance, SteriPack's services to the pharmaceutical industry include device design and development, final assembly, labelling, secondary packing, serialisation and aggregation of injectable formats including vials, pre-filled syringes, and autoinjectors. SteriPack's tailored customer-focused solutions make it an ideally suited supplier for small to medium-sized batch volumes required for a growing market of targeted therapies as well as clinical trials. Its proven capabilities in cleanroom assembly and labelling as well as secondary packing services for drug delivery systems and medical devices, combined with significant investment into growing cold chain storage capacity, have helped to make it a trusted partner to top global pharmaceutical companies.

Read More

Medical Devices

Canon Medical Systems and Olympus Announce Business Alliance regarding Endoscopic Ultrasound Systems

Canon Medical Systems | January 15, 2024

Canon Medical Systems Corporation and Olympus Corporation announced that we have reached an agreement to collaborate on Endoscopic Ultrasound Systems. Canon Medical will develop and manufacture diagnostic ultrasound systems used in Endoscopic Ultrasonography1 (EUS), and Olympus will perform the sales and marketing efforts. The aim of this collaboration between Canon's Aplio i8002 diagnostic ultrasound system for EUS and Olympus' Ultrasound Endoscope3 is to provide the market with advanced EUS equipment capable of delivering high-quality image diagnoses. Canon Medical and Olympus are focusing on technological advancements and enhancing diagnostic performance in the EUS field, with plans for global expansion, starting in Japan and Europe. Canon Medical has a history of more than 100 years in the diagnostic imaging systems business, including X-ray diagnostic systems, CT, MRI, and ultrasound diagnostic systems, and provides products and services to more than 150 countries and regions worldwide. Canon Medical has been a leading company in the development of diagnostic ultrasound systems since the 1960s and has pioneered the development of A-mode (Amplitude display mode) systems for neurosurgery and linear electronic scanning systems, among others. Canon Medical's strengths lie in its advanced ultrasound image quality and proprietary technologies, such as D-THI, an image quality enhancement technology, and SMI, an imaging technology that enables the delineation of extremely slow and fine blood flow, which has been difficult to image in the past. Olympus has contributed to elevating the standard of care through early detection, diagnosis and staging, and minimally invasive treatment since developing the world’s first practical gastrocamera. In the field of EUS, Olympus has worked closely with physicians to develop new equipment to enhance imaging and diagnostic methods and expand procedures, helping gain and maintain a high share of the global market. Through our collaboration, the two companies will achieve further qualitative improvements in the quality of images and performance in diagnosis and minimally invasive treatment of EUS, ultimately contributing to facilitate the early detection of diseases. Comment from Toshio Takiguchi, President and CEO, Canon Medical Systems Corporation “We have been promoting our business with diagnostic imaging at its core under the philosophy of 'Made for Life,' which expresses our desire to contribute to medical care that protects precious lives. We have a long history in diagnostic ultrasound systems and have developed unique technologies that contribute to the early detection of diseases in cooperation with doctors around the world. We are very pleased to collaborate with Olympus, a leading endoscope manufacturer, in the EUS field, which we have not been able to cover adequately until now, to deliver superior solutions to more patients.” Comment from Frank Drewalowski, Executive Officer and Endoscopic Solutions Division Head, Olympus Corporation “Olympus aims to improve patients’ quality of life through early diagnosis made available with Endoscopic Ultrasound Systems. In the field of EUS, diagnostic ultrasound systems are very important, and we are pleased to have a cooperative relationship with Canon Medical, which has advanced ultrasound imaging technology. Canon Medical and Olympus will continue to introduce products and technology that address the needs of the patients, healthcare professionals, and the broader medical industry.” This examination uses ultrasound attached to the tip of an endoscope to observe the outer organs (pancreas, gallbladder, bile ducts, liver, etc.) from the stomach and duodenum. Compared to the approach from the body surface, the target organs can be observed at close range, allowing detailed diagnosis with clearer images. In the diagnosis of pancreatic cancer, EUS is recognized as having the same diagnostic capability as contrast-enhanced CT and MRI in the "Guidelines for Pancreatic Cancer Treatment (2022)" in Japan. EUS-FNA (Endoscopic Ultrasonography-FNA: a test to collect tumor cells using an ultrasound endoscope) enables qualitative tissue diagnosis by minimally invasive cell and tissue collection and is established worldwide as a diagnostic method when pancreatic cancer is suspected. In addition to endoscopic retrograde cholangiopancreatography (ERCP), which is the first choice for stent placement for obstructive jaundice, endoscopic ultrasound-assisted biliary drainage (EUS-BD) using the EUS-FNA technique is now available. With the advent of these devices, the endoscopic treatment area of Interventional EUS has been attracting increasing attention in recent years. About Canon Medical Systems Canon Medical offers a full range of diagnostic medical imaging solutions including CT, Diagnostic and Interventional X-ray, Ultrasound and MR, as well as a full suite of Healthcare IT solutions, across the globe. In line with our continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features. At Canon Medical, we work hand in hand with our partners - our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life About Olympus At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world.

Read More

Spotlight

AdviNOW Medical

AdviNOW Medical

Founded in 2016 to revolutionize healthcare through automation and artificial intelligence (AI), bringing top-tier technology and process design to patient engagement and provider consultation. Our mission is to enable providers to deliver the best on-demand experience while accelerating operations,...

Events

Resources